455 filings
Page 4 of 23
6-K
d4bs5k7lhcosgn6 qyp2
31 Mar 23
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
6:06am
6-K
myl kdegy1bv33
14 Mar 23
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
9:46am
6-K
5khvnij1fdj 9b2l
8 Mar 23
Current report (foreign)
6:04am
6-K
0x88uu96yex8afcdq2y
6 Mar 23
Vesting of awards under the Long Term Incentive Plan
6:01am
6-K
m3zkr4ohcu9qu4n
28 Feb 23
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
6:09am
6-K
ryg d5z8ua7e56e
27 Feb 23
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
6:29am
6-K
w7tntmlmq7z
31 Jan 23
HUTCHMED to Announce 2022 Final Results
6:03am
6-K
qnwe08plh
23 Jan 23
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
6:39am
6-K
m03it5ou
18 Jan 23
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
9:13pm
6-K
ll63qd5jy53t
3 Jan 23
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
6:01am
6-K
2pwczzcg2u
30 Dec 22
Current report (foreign)
6:05am
6-K
67gosetef we5m68
19 Dec 22
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
6:01am
6-K
2h73cf
15 Nov 22
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
6:03am
6-K
6oly37uvjmhc8e2o5hcb
14 Nov 22
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
6:14am
6-K
udiju81rk
27 Oct 22
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
7:38am
6-K
kiew0y3en31
21 Oct 22
Vesting of awards under the Long Term Incentive Plan
6:09am
6-K
tg5ol
11 Oct 22
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
6:49am
6-K
s5rw lkqjz7s71rt8
30 Sep 22
Current report (foreign)
6:02am
6-K
4kf 75bsc
14 Sep 22
Grant of Share Options under Share Option Scheme and Awards under
6:17am